Everything you need to know about Amanta Healthcare IPO

About

Amanta Healthcare is a pharmaceutical formulation manufacturer incorporated in 1994. The company specialises in sterile liquid formulations and operates across multiple therapeutic segments, including fluid therapy, respiratory care, ophthalmic, diluents, and irrigation solutions. Its manufacturing facility, located in Hariyala, Kheda district, Gujarat, is spread across over 66,000 square meters and is equipped with multiple LVP and SVP lines using ABFS and ISBM technologies. The company is WHO-GMP compliant and holds ISO 9001:2015, ISO 13485:2016, ISO 14001:2015, and ISO 45001:2018 certifications.

IPO schedule

Issue open date 2025-09-01
Issue close date 2025-09-03
UPI mandate deadline 2025-09-03 (5 PM)
Allotment finalization 2025-09-04
Refund initiation 2025-09-08
Share credit 2025-09-08
Listing date 2025-09-09
Mandate end date 2025-09-18
Lock-in end date for anchor investors (50%) 2025-10-04
Lock-in end date for anchor investors (remaining) 2025-12-03

Financials

Financial Year Ended March 2023 March 2024 March 2025
Total Assets 374.06 352.11 381.76
Revenue 262.69 281.60 276.09
Profit After Tax -2.11 3.63 10.50

Issue size

Funds Raised in the IPO Amount
Overall ₹126 crores
Fresh Issue ₹126 crores

Utilisation of proceeds

Purpose INR crores (%)
Capital expenditure for setting up a new manufacturing line of SteriPort 70 (55.5%)
Capital expenditure for setting up a new manufacturing line for SVP 30.13 (24%)
General corporate purposes 25.87 (20.5%)

Strengths

  • Established in 1994 with a diversified pharmaceutical product portfolio
  • Advanced sterile liquid manufacturing across a wide volume range
  • Certified facility with ISO, WHO-GMP, and advanced technologies
  • Extensive domestic and global distribution and sales network
  • Experienced leadership with a skilled, qualified employee base

Risk factors

  • High customer concentration poses revenue stability and dependency risks
  • Delay in SteriPort/SVP expansion may impact growth plans
  • Promoter guarantees tied to loans may affect operations
  • Sterile liquid products carry serious product liability exposure
  • Unsecured borrowings and personal guarantees increase financial vulnerability